/RGC
RGC Stock - Regencell Bioscience Holdings Limited
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$19.81+4.70%
+$0.89 (+4.70%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.38
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $21.79
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RGC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$19.61 – $20.01
TARGET (TP)$22.78
STOP LOSS$18.23
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.06
52W High$83.60
52W Low$0.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-392,743 | $-745,588 | $-769,687 | $-604,397 | $-26,456 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,769,985 | $-4,736,726 | $-6,273,671 | $-7,617,770 | $-1,381,362 |
| Net Income | $-3,584,213 | $-4,301,837 | $-5,871,130 | $-7,422,728 | $-1,346,745 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.00 |
Company Overview
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RGCBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.14
Q1 2025
EPS Surprise History
Q4 19
No data
Q2 20
No data
Q4 20
No data
Q4 21
No data
Q1 23
No data
Q2 23
No data
Q1 24
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 24, 2025 | — | — | — | — |
Q3 2025 | Jul 16, 2025 | — | — | — | — |
Q1 2025 | Jan 24, 2025 | — | $-0.14 | — | — |
Q4 2024 | Oct 25, 2024 | — | — | — | — |
Q1 2024 | Jan 26, 2024 | — | $0.00 | — | — |
Q4 2023 | Oct 27, 2023 | — | — | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Jan 30, 2023 | — | $-0.01 | — | — |
Q4 2022 | Oct 31, 2022 | — | — | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 30, 2020 | — | $0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $0.00 | — | — |
Q4 2019 | Dec 30, 2019 | — | $0.00 | — | — |
Latest News
Regencell Bioscience shares are trading lower after the company received a subpoena indicating the DOJ is conducting an investigation into the trading in its Ordinary Shares. Additionally, the company said there is substantial doubt about its ability to continue as a going concern.
📉 NegativeBenzinga•Nov 3, 2025, 07:49 PM
Regencell stock rally returns as company blames short selling for volatility
📈 PositiveSeeking Alpha•Jul 3, 2025, 04:18 PM
Regencell resumes rally as stock split takes effect
📈 PositiveSeeking Alpha•Jun 16, 2025, 02:46 PM
This biotech has posted 145-fold YTD jump with entire rally attributed to narrative
➖ NeutralSeeking Alpha•Jun 6, 2025, 05:56 PM
Frequently Asked Questions about RGC
What is RGC's current stock price?
Regencell Bioscience Holdings Limited (RGC) is currently trading at $19.81 per share. The stock has moved +4.70% today.
What is the analyst price target for RGC?
No analyst price targets are currently available for this stock.
What sector is Regencell Bioscience Holdings Limited in?
Regencell Bioscience Holdings Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is RGC's market cap?
Regencell Bioscience Holdings Limited has a market capitalization of $9.80 billion, making it a mid-cap company.
Does RGC pay dividends?
No, Regencell Bioscience Holdings Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
ATR
AptarGroup, Inc.
$121.39
Mkt Cap: $8.0B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
GRFS
Grifols, S.A.
$9.02
Mkt Cap: $7.6B
MASI
Masimo Corporation
$134.04
Mkt Cap: $7.2B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
STVN
Stevanato Group S.p.A.
$20.53
Mkt Cap: $5.6B
Explore stocks similar to RGC for comparison